tetano
Editor, Senior Moderator
Front Pediatr
. 2024 Apr 5:12:1351478.
doi: 10.3389/fped.2024.1351478. eCollection 2024. A case report and literature review on tocilizumab-cured acute necrotizing encephalopathy caused by influenza A virus
YuKun Huang[SUP] 1 [/SUP], Bin Zhou[SUP] 1 [/SUP], ShaoXian Hong[SUP] 1 [/SUP], YaLi Cai[SUP] 1 [/SUP]
Affiliations
Introduction: Acute Necrotizing Encephalopathy (ANE), is a kind of severe Central Nervous System Disease. The commonest pathogen is the influenza virus. The pathogenesis of ANE is bound up to genetic susceptibility and cytokine storm. Interleukin-6 (IL-6) is deemed as the core function in cytokine storm of ANE and that plays a significant role in evaluating the severity of Influenza-Related ANE. Tocilizumab, an IL-6 antagonist, is known to be safe and effective in the treatment of ANE when used early and has an essential role in improving prognosis and preventing disability.
Case report: This case reports a 2 year 10 month old boy who developed ANE after being infected with influenza A virus (H1N1-2019). After treatment with Tocilizumab, the child's consciousness was clear, no convulsions occurred, the movement of limbs was improved, and the lesions of encephalopathy were significantly reduced.
Conclusion: The early use of Tocilizumab is safe and effective for the treatment of ANE caused by influenza virus.
Keywords: Tolizumab; acute necrotizing encephalopathy; children; cytokine storm; influenza A virus; interleukin-6; prognosis.
. 2024 Apr 5:12:1351478.
doi: 10.3389/fped.2024.1351478. eCollection 2024. A case report and literature review on tocilizumab-cured acute necrotizing encephalopathy caused by influenza A virus
YuKun Huang[SUP] 1 [/SUP], Bin Zhou[SUP] 1 [/SUP], ShaoXian Hong[SUP] 1 [/SUP], YaLi Cai[SUP] 1 [/SUP]
Affiliations
- PMID: 38646514
- PMCID: PMC11026575
- DOI: 10.3389/fped.2024.1351478
Introduction: Acute Necrotizing Encephalopathy (ANE), is a kind of severe Central Nervous System Disease. The commonest pathogen is the influenza virus. The pathogenesis of ANE is bound up to genetic susceptibility and cytokine storm. Interleukin-6 (IL-6) is deemed as the core function in cytokine storm of ANE and that plays a significant role in evaluating the severity of Influenza-Related ANE. Tocilizumab, an IL-6 antagonist, is known to be safe and effective in the treatment of ANE when used early and has an essential role in improving prognosis and preventing disability.
Case report: This case reports a 2 year 10 month old boy who developed ANE after being infected with influenza A virus (H1N1-2019). After treatment with Tocilizumab, the child's consciousness was clear, no convulsions occurred, the movement of limbs was improved, and the lesions of encephalopathy were significantly reduced.
Conclusion: The early use of Tocilizumab is safe and effective for the treatment of ANE caused by influenza virus.
Keywords: Tolizumab; acute necrotizing encephalopathy; children; cytokine storm; influenza A virus; interleukin-6; prognosis.